Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740934 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea
A NA study of Rosacea, sponsored by Rock Creek Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 3
- Study locations
NCT01740934: Completed NA study of Rosacea, sponsored by Rock Creek Pharmaceuticals.
NCT01740934 is a NA study of Rosacea that has completed, run by Rock Creek Pharmaceuticals. The registered enrollment target is 117 participants, below the 238-participant average among 23 other Rosacea trials with a reported enrollment target (51% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01740934, a NA study of Rosacea, has completed, sponsored by Rock Creek Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial Cream improves the appearance of the skin in subjects with mild to moderate rosacea.
Primary Outcome
Collected information of the safety, tolerability and adverse events, and subjective experience related to the use of Anatabloc Cream by subjects
Conditions Studied
Interventions
- OTHER Placebo Cream
- OTHER Anatabloc Cream
Study Locations (3)
Florida
- Susan H. Weinkle, MD - Bradenton
Louisiana
- Lupo Center for Aesthetic & General Dermatology - New Orleans
New York
- Diane Berson, MD - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-08 |
| Phase | NA |
What the finished NCT01740934 record still lists
NCT01740934 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 238-participant average among 23 other Rosacea trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Placebo Cream is the first listed.
NCT01740934 reports a single indexed study location in Florida, Louisiana, New York.
Frequently Asked Questions
What is clinical trial NCT01740934 about?
NCT01740934 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea". This is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of Anatabloc Facial Cream. The secondary aim is to evaluate if Anatabloc Facial ...
What is the current status of trial NCT01740934?
This trial is currently completed. It is a NA study. The enrollment target is 117 participants. The study started on 2012-11. Estimated completion is 2013-08.
What conditions does trial NCT01740934 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01740934?
The interventions under investigation include: Placebo Cream (OTHER), Anatabloc Cream (OTHER).
Who is sponsoring clinical trial NCT01740934?
This trial is sponsored by Rock Creek Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01740934 being conducted?
This trial has 3 study locations across Florida, Louisiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01740934's enrollment target sits among peer trials
117 12th of 23 higher than 12 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
4 Week In-Use Study Evaluating How Well-Tolerated a Skin Care Product Is on Adults With Facial Redness
COMPLETED · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
-
Analysis of the Microbiome in Rosacea
ACTIVE NOT RECRUITING · Early Phase 1
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia